{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-072982","form_type":"8-K","ticker":"TNON","cik":"0001560293","company_name":"Tenon Medical, Inc.","filed_at":"2024-08-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.514501+00:00","generated_at":"2026-05-31T07:23:38.121416+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Tenon Medical appoints Kevin Williamson as CFO effective Sept 3, 2024","bullets":["Appointed Kevin Williamson as CFO, effective Sept 3, 2024, succeeding retiring CFO Steve Van Dick.","Compensation: $315,000 base salary, bonus up to 30% of base, RSU of 50,000 shares with 3-year vesting.","Williamson most recently CFO at Accelus Inc., prior roles at NuVasive; holds B.S. and MBA.","Company cites upcoming catalysts: full enrollment of post-market clinical trial for Catamaran SI Joint Fusion System.","Severance: 100% of base salary for 12 months if terminated without cause."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-072982","json":"https://secwatch.observer/filing/0001213900-24-072982.json","markdown":"https://secwatch.observer/filing/0001213900-24-072982.md","text":"https://secwatch.observer/filing/0001213900-24-072982.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1560293/000121390024072982/0001213900-24-072982-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1560293/000121390024072982/ea0212316-8k_tenon.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:23:38.121416+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a72f47d872","claim":"Kevin Williamson was appointed as Chief Financial Officer at Tenon Medical, Inc..","evidence_excerpt":"On August 20, 2024, Tenon Medical, Inc. (the “Company”) entered into an offer letter (the “Letter”) with Kevin Williamson pursuant to which Mr. Williamson was appointed as Chief Financial Officer of the Company, effective as of September 3, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1560293/000121390024072982/0001213900-24-072982-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}